<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03216902</url>
  </required_header>
  <id_info>
    <org_study_id>012601IN</org_study_id>
    <nct_id>NCT03216902</nct_id>
  </id_info>
  <brief_title>A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study</brief_title>
  <official_title>A Phase IIb, Randomized, Observer-Masked, Placebo- and Active-Controlled, Parallel-Group, Multinational and Multicenter Study Assessing the Safety and Efficacy of DE-126 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Santen Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Santen Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment of elevated pressure in the eye (Intraocular pressure, or 'IOP') with eye drop
      medications has been shown to be effective in delaying or preventing the progression of
      glaucoma, and it is the only proven method for reducing the risk of glaucomatous visual field
      loss.

      This study is being conducted to determine how well DE-126 ophthalmic solution works
      (efficacy) in safely lowering IOP when dosed as topical eyedrops. This study will evaluate
      the safety and efficacy of four (4) concentrations of DE-126, when compared with latanoprost
      (0.005%) eye drops in patients with primary open-angle glaucoma or ocular hypertension.

      The IOP will be measured at 3 different times throughout the day, over 6 total visits during
      a 3-month treatment period (with up to 4 extra weeks observation if the patient must stop
      taking current eye drops to lower IOP). Safety assessments will be done throughout the study,
      including ocular signs and symptoms, vital signs, and clinical laboratory tests. While the
      most important time-point to measure IOP in this study and evaluate efficacy will be at the
      final study visit (month 3), IOP values will also be evaluated at other visits throughout the
      3-month treatment period.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 25, 2017</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraocular Pressure in the study eye at 3 time-points throughout the day</measure>
    <time_frame>Three months</time_frame>
    <description>Intraocular Pressure in the study eye at 3 time-points throughout the day at Month 3</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intraocular Pressure in the study eye at 3 time-points throughout the day at week 6</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraocular Pressure in the study eye at 3 time-points throughout the day at weeks 1 and 2</measure>
    <time_frame>up to 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean diurnal Intraocular Pressure in the study eye at weeks 1, 2, 6 and month 3</measure>
    <time_frame>up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change and percent change from baseline (CFB) in mean diurnal Intraocular Pressure in the study eye at each post-baseline visit</measure>
    <time_frame>up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change and percent change from baseline (CFB) in Intraocular Pressure in the study eye at three time points at each post-baseline visit</measure>
    <time_frame>up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with mean diurnal Intraocular Pressure reduction from baseline ≥ 20%, 25% and 30% in the study eye at each post-baseline visit</measure>
    <time_frame>up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with mean diurnal Intraocular Pressure ≤ 18 mmHg in the study eye at each post-baseline visit</measure>
    <time_frame>up to 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Open-angle Glaucoma, Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>Placebo (Vehicle of DE-126) followed by high dose of DE-126</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ultra-low dose DE-126</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose DE-126</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium dose DE-126</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose of DE-126</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0.005% Latanoprost</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle of DE-126 Ophthalmic Solution, high dose of DE-126 Ophthalmic Solution</intervention_name>
    <description>Vehicle of DE-126 Ophthalmic Solution dosed once daily for 6weeks, followed by high dose of DE-126 dosed once daily for 6 additional weeks</description>
    <arm_group_label>Placebo (Vehicle of DE-126) followed by high dose of DE-126</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical ultra-low dose of DE-126 Ophthalmic Solution</intervention_name>
    <description>Topical ultra-low dose of DE-126 Ophthalmic Solution dosed once daily for 12 weeks</description>
    <arm_group_label>Ultra-low dose DE-126</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical low dose of DE-126 Ophthalmic Solution</intervention_name>
    <description>Topical low dose of DE-126 Ophthalmic Solution dosed once daily for 12 weeks</description>
    <arm_group_label>Low dose DE-126</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical medium dose of DE-126 Ophthalmic Solution</intervention_name>
    <description>Topical medium dose of DE-126 Ophthalmic Solution dosed once daily for 12 weeks</description>
    <arm_group_label>Medium dose DE-126</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical high dose of DE-126 Ophthalmic Solution</intervention_name>
    <description>Topical high dose of DE-126 Ophthalmic Solution dosed once daily for 12 weeks</description>
    <arm_group_label>High dose of DE-126</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.005% Latanoprost Ophthalmic Solution</intervention_name>
    <description>0.005% Latanoprost Ophthalmic Solution dosed once daily for 12 weeks</description>
    <arm_group_label>0.005% Latanoprost</arm_group_label>
    <other_name>Xalatan®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provide signed written informed consent

          -  Diagnosis of POAG or OHT in both eyes

          -  Qualifying corrected visual acuity in each eye

          -  Qualifying central corneal thickness in each eye

          -  Qualifying Day 1 IOP measurement at 3 time-points in both eyes

          -  Qualifying Anterior chamber angle

        Exclusion Criteria:

          -  History of ocular surgery specifically intended to lower IOP

          -  Subjects who cannot safely discontinue use of ocular hypotensive medications during
             the wait/washout period

          -  Advanced glaucoma in either eye

          -  Any corneal abnormality or other condition interfering with or preventing reliable
             Goldmann applanation tonometry

          -  Any ocular surgery or ocular laser treatment within 90 days prior to Visit 1
             (Screening) and throughout the study in either eye

          -  Females who are pregnant, nursing, or planning a pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Santen Inc. Clinical Operations</last_name>
    <phone>+1 415-268-9100</phone>
    <email>clinicaltrials@santeninc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sall Research Medical Center, Inc</name>
      <address>
        <city>Artesia</city>
        <state>California</state>
        <zip>90701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>clinicaltrials@santeninc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>North Valley Eye Medical Group</name>
      <address>
        <city>Mission Hills</city>
        <state>California</state>
        <zip>91345</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>clinicaltrials@santeninc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eye Research Foundation, INC</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92657</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>clinicaltrials@santeninc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>North Bay Eye Associates, Inc.</name>
      <address>
        <city>Petaluma</city>
        <state>California</state>
        <zip>94954</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>clinicaltrials@santeninc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shettle Eye Research, Inc.</name>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <zip>33773</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>clinicaltrials@santeninc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clayton Eye Clinical Research, LLC</name>
      <address>
        <city>Morrow</city>
        <state>Georgia</state>
        <zip>30260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>clinicaltrials@santeninc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Coastal Research Associates, LLC</name>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <zip>30076</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>clinicaltrials@santeninc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rochester Ophthalmological Group, PC</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>clinicaltrials@santeninc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mundorf Eye Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>clinicaltrials@santeninc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cornerstone Health Care, LLC</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>clinicaltrials@santeninc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Keystone Research Ltd SMO/Texan Eye, PA</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>clinicaltrials@santeninc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Keystone Research LTD SMO/Medical Center Ophthalmology Assoc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>clinicaltrials@santeninc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Murakami Karindoh Hospital</name>
      <address>
        <city>Fukuoka-shi, Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>clinical@santen.co.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nagasaka Eye Clinic</name>
      <address>
        <city>Nagoya-shi, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>clinical@santen.co.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sugiura Eye Clinic</name>
      <address>
        <city>Osaka-shi, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>clinical@santen.co.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sapporo Katoh Ophthalmology Clinic</name>
      <address>
        <city>Sapporo-shi, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>clinical@santen.co.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dogenzaka Kato Eye Clinic</name>
      <address>
        <city>Shibuya-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>clinical@santen.co.jp</email>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2017</study_first_submitted>
  <study_first_submitted_qc>July 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2017</study_first_posted>
  <last_update_submitted>September 3, 2017</last_update_submitted>
  <last_update_submitted_qc>September 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glaucoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Latanoprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

